Weight-loss drug forecasts jump to $150 billion as supply grows

As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly , increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.

Related Keywords

Hillerod , Hovedstaden , Denmark , United States , Americans , Lilly Zepbound , Michael Kleinrock , Novo Wegovy , Eli Lilly , Amgen Maritide , Institute For Data Science , Novo Nordisk , Reuters , Amgen , David Song , Tema Obesity ,